WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Biotage AB, Sweden
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Medical
Alterity Therapeutics | June 03, 2022
Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...
MedTech
ElevateBio, LLC | November 07, 2022
ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, announced the unveiling of ElevateBio BaseCamp’s proprietary LentiPeakTM lentiviral vector platform. LentiPeak is a serum-free, suspension-based, scalable production platform that has demonstrated high volumetric productivity of therapeutically relevant vector yields that meet regulatory guidelines. LentiPeak will enable efficient transition for cell and gene therapie...
Industrial Impact
Precigen, Inc. | July 06, 2022
Precigen, Inc. a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced that the Company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C. an industry-leading animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership, for $170 million in upfront cash and up to $10 million earn-out ba...
PR Newswire | July 29, 2020
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for its CiVax™ program (heat stable COVID-19 vaccine), demonstrating immunity of both broad-spectrum antibody and cell-mediated, rapid onset immunity is possible using the CoVaccine HT™ (CoVaccine) adjuvant.&nbs...
Video
Industry Outlook
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE